LPGAT1 Double Nickase Plasmid (h): sc-411390-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LPGAT1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- LPGAT1 Double Nickase Plasmid (h) and LPGAT1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting LPGAT1. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LPGAT1 Double Nickase Plasmid (h) | sc-411390-NIC | 20 µg | $410.00 |
LPGAT1 (lysophosphatidylglycerol acyltransferase 1) encodes an acyltransferase that catalyzes reacylation of lysophosphatidylglycerol to phosphatidylglycerol, helping maintain glycerophospholipid homeostasis and membrane composition. By shaping phospholipid remodeling within the Lands’ cycle, LPGAT1 influences membrane biogenesis, organelle function, and lipid-mediated signaling processes. Perturbation of phospholipid acyl-chain composition is linked to metabolic stress, mitochondrial and ER membrane dysfunction, and altered cellular bioenergetics, making LPGAT1 relevant for studies of lipid metabolism and membrane-associated phenotypes. Dysregulated lipid remodeling pathways have been associated with cardiometabolic and liver-related traits in genetic and functional studies, supporting investigation of LPGAT1 in disease-relevant cellular models.
LPGAT1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the LPGAT1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within LPGAT1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt LPGAT1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of LPGAT1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.